CLINICAL_TRIALS
trial_result
· 2017-09-12
Clinical Trial Update: Erlotinib as Neoadjuvant Treatment in Patients With Stage ⅢA N2 NSCLC With Activating EGFR Mutation. [Phase 2]
Summary
Phase 2 trial evaluating erlotinib as neoadjuvant treatment in stage IIIA N2 non-small cell lung cancer with activating EGFR mutation has completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Baohui Han | Conditions: Non Small Cell Lung Cancer | Phase 2 | Status: COMPLETED